Pharmaceutical Business review

Harvard University and Oxford Nanopore sign licensing agreement

Under the terms of this agreement with Harvard, Oxford Nanopore has exclusive rights to develop and commercialize a number of nanopore technological breakthroughs developed in the laboratories of three investigators at Harvard and their collaborators at the University of California Santa Cruz and the National Institute of Standards and Technology, an agency of the US Department of Commerce.

Oxford Nanopore will also support fundamental nanopore research at Harvard, facilitating further advancement of the field and generating opportunities for further evolutions of nanopore sequencing technology.

Gordon Sanghera, CEO of Oxford Nanopore, said: “Through this partnership and agreements with other prestigious institutions, Oxford Nanopore takes the leading position in transforming nanopores from science into technologies that will benefit researchers and people everywhere.”